SCHEMBL8118554

SCHEMBL8118554

CCNC(N)c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 1/20 0.45
DPP4 P27487 2/20 0.44
F2 P00734 1/20 0.44
MTOR P42345 1/20 0.43
RAB9A P51151 1/20 0.43
GRM7 Q14831 1/20 0.43
AOC3 Q16853 1/20 0.42
TAAR1 Q96RJ0 3/20 0.41
LMNA P02545 2/20 0.41
CYP3A4 P08684 1/20 0.41
ALOX15 P16050 1/20 0.41
TSHR P16473 1/20 0.41
HTR2A P28223 1/20 0.41
ADRA2A P08913 1/20 0.40
ADRA2C P18825 1/20 0.40
HIF1A Q16665 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10764905 0.83 SIGMAR1 (0.48) SIGMAR1DPP4F2MTORRAB9A
SCHEMBL27666196 0.78 SIGMAR1 (0.31) SIGMAR1
SCHEMBL8829326 0.78 ALDH1A1 (0.50) SIGMAR1MTORRAB9AGRM7LMNA
SCHEMBL4347120 0.77 NAAA (0.50) SIGMAR1HTR2A
SCHEMBL1485821 0.76 SIGMAR1 (0.48) SIGMAR1MTORRAB9AGRM7AOC3
SCHEMBL14139798 0.76 SIGMAR1 (0.48) SIGMAR1MTORRAB9AGRM7AOC3
SCHEMBL5077174 0.76 MTOR (0.65) SIGMAR1MTORRAB9AGRM7LMNA
SCHEMBL17468631 0.76 ACP3 (0.50) SIGMAR1DPP4CYP3A4
SCHEMBL16614038 0.76 ACP3 (0.50) SIGMAR1DPP4CYP3A4
SCHEMBL26414224 0.75 DPP4 (0.52) DPP4F2TAAR1LMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1037633-A1 ANTIVIRAL COMPOUNDS BIOCHEM PHARMA INC (CA) 2000-09-27 EP claimed
WO-1999029318-A1 ANTIVIRAL COMPOUNDS BIOCHEM PHARMA INC. (CA) 1999-06-17 WO claimed
US-20180155325-A1 COMPOUND FOR ORGANIC OPTOELECTRONIC DEVICE, COMPOSITION FOR ORGANIC OPTOELECTRONIC DEVICE AND ORGANIC OPTOELECTRONIC DEVICE AND DISPLAY DEVICE SAMSUNG SDI CO., LTD. (KR) 2018-06-07 US disclosed
US-20180155325-A1 COMPOUND FOR ORGANIC OPTOELECTRONIC DEVICE, COMPOSITION FOR ORGANIC OPTOELECTRONIC DEVICE AND ORGANIC OPTOELECTRONIC DEVICE AND DISPLAY DEVICE SAMSUNG SDI CO., LTD. (KR) 2018-06-07 US disclosed
EP-1037633-A1 ANTIVIRAL COMPOUNDS BIOCHEM PHARMA INC (CA) 2000-09-27 EP disclosed
WO-1999029318-A1 ANTIVIRAL COMPOUNDS BIOCHEM PHARMA INC. (CA) 1999-06-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180155325-A1 COMPOUND FOR ORGANIC OPTOELECTRONIC DEVICE, COMPOSITION FOR ORGANIC OPTOELECTRONIC DEVICE AND ORGANIC OPTOELECTRONIC DEVICE AND DISPLAY DEVICE OXER1, OCIAD1, OR10J3 SIGMAR1 386/4885DPP4 4324/4885F2 1869/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.